Anti-infective pharmacodynamics - Maximizing efficacy, minimizing toxicity

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 4, 2004, Pages 505-512

  Jacobs, Michael R ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFDINIR; CEFIXIME; CEFPROZIL; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; LINCOMYCIN; LINEZOLID; MOXIFLOXACIN; PENICILLIN G; RIFAMPICIN; ROXITHROMYCIN; TELITHROMYCIN; TETRACYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS;

EID: 13344281986     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.10.010     Document Type: Review

References (42)

1. W.A. Craig Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men Clin. Infect. Dis. 26 1998 1-10 (quiz 11-12)
2. D. Andes et al. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections Clin. Lab. Med. 24 2004 477-502
3. M.R. Jacobs Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters Clin. Microbiol. Infect. 7 2001 589-596
4. W.A. Craig Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid Infect. Dis. Clin. North Am. 17 2003 479-501
5. S.L. Preston et al. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials J. Am. Med. Assoc. 279 1998 125-129
6. R. Dagan Achieving bacterial eradication using pharmacokinetic/pharmacodynamic principles Int. J. Infect. Dis. 7 Suppl. 1 2003 S21-S26
7. M.J. Rybak et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity Antimicrob. Agents Chemother. 43 1999 1549-1555
8. J. Turnidge Pharmacodynamics and dosing of aminoglycosides Infect. Dis. Clin. North Am. 17 2003 503-528
9. American Academy of Pediatrics and American Academy of Family Physicians Diagnosis and management of acute otitis media Pediatrics 113 2004 1451-1465
10. J.B. Anon et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis Otolaryngol. Head Neck Surg. 130 1 Suppl. 2004 1-45
11. W.A. Craig Antimicrobial resistance issues of the future Diagn. Microbiol. Infect. Dis. 25 1996 213-217
12. C.D. Marchant et al. Measuring the comparative efficacy of antibacterial agents for acute otitis media: The "Pollyanna phenomenon" J. Pediatr. 120 1992 72-77
13. T.M. File Jr. et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia Chest 125 2004 1888-1901
14. M.J. Fine et al. A prediction rule to identify low-risk patients with community-acquired pneumonia N. Engl. J. Med. 336 1997 243-250
15. G.L. Drusano et al. Moxalactam and piperacillin: A study of in vitro characteristics and pharmacokinetics in cancer patients Infection 13 1985 20-26
16. E.E. Dagrosa et al. Multiple-dose pharmacokinetics of ofloxacin, a new broad-spectrum antimicrobial agent Clin. Ther. 8 1986 632-645
17. H.C. Neu General concepts on the chemotherapy of infectious diseases Med. Clin. North Am. 71 1987 1051-1064
18. B. Vogelman W.A. Craig Kinetics of antimicrobial activity J. Pediatr. 108 5 Pt 2 1986 835-840
19. B. Vogelman et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model J. Infect. Dis. 158 1988 831-847
20. C. Kaito et al. Silkworm larvae as an animal model of bacterial infection pathogenic to humans Microb. Pathog. 32 2002 183-190
21. H. Hamamoto et al. Quantitative evaluation of the therapeutic effects of antibiotics using silkworms infected with human pathogenic microorganisms Antimicrob. Agents Chemother. 48 2004 774-779
22. S.L. Preston et al. Pharmacodynamics and clinical use of anti-HIV drugs Infect. Dis. Clin. North Am. 17 2003 651-674
23. D. Andes Clinical pharmacodynamics of antifungals Infect. Dis. Clin. North Am. 17 2003 635-649
24. G. Edwards S. Krishna Pharmacokinetic and pharmacodynamic issues in the treatment of parasitic infections Eur. J. Clin. Microbiol. Infect. Dis. 23 2004 233-242
25. S. Carryn et al. Intracellular pharmacodynamics of antibiotics Infect. Dis. Clin. North Am. 17 2003 615-634
26. Lietman, P.S. (1985) Pharmacokinetics of antimicrobial agents. In Principles and Practices of Infectious Diseases (Vol. Chapter 16) (Mandell, G.L., Douglas, R.G. Jr, Bennett, J.E., eds), pp. 164-166, John Wiley & Sons
27. Abdel-Rahman, S.M. and Kearns, G.L. (2004) The pharmacokinetic-pharmacodynamic interface: Determinants of anti-infective drug action and efficacy in pediatrics. In Textbook of Pediatric Infectious Diseases (Vol. Chapter 234) (Feigin, R.D., Cherry, J.D., Demmler, G.J., Kaplan, S.L., eds), pp. 2965-2987, Saunders
28. I. Odenholt et al. Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens Antimicrob. Agents Chemother. 45 2001 23-29
29. C.H. Nightingale Pharmacokinetics and pharmacodynamics of newer macrolides Pediatr. Infect. Dis. J. 16 1997 438-443
30. G.L. Drusano et al. Relationship between fluoroquinolone area under the curve: Minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia J. Infect. Dis. 189 2004 1590-1597
31. J.K. Thomas et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy Antimicrob. Agents Chemother. 42 1998 521-527
32. A. Forrest et al. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis J. Antimicrob. Chemother. 40 Suppl. A 1997 45-57
33. W.A. Craig D. Andes Pharmacokinetics and pharmacodynamics of antibiotics in otitis media Pediatr. Infect. Dis. J. 15 1996 255-259
34. J.M. Hyatt et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents Clin. Pharmacokinet. 28 1995 143-160
35. D. Andes et al. In vivo pharmacodynamics of a new oxazolidinone (linezolid) Antimicrob. Agents Chemother. 46 2002 3484-3489
36. J.E. Leggett et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models J. Infect. Dis. 159 1989 281-292
37. W.A. Craig The pharmacology of meropenem, a new carbapenem antibiotic Clin. Infect. Dis. 24 Suppl. 2 1997 S266-S275
38. R.J. Whitley Herpes simplex virus infection Semin. Pediatr. Infect. Dis. 13 2002 6-11
39. J.W. Mouton Impact of pharmacodynamics on breakpoint selection for susceptibility testing Infect. Dis. Clin. North Am. 17 2003 579-598
40. M.R. Jacobs et al. Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998-2001 U.S. Surveillance Study Clin. Lab. Med. 24 2004 503-530
41. NCCLS (2004) Performance Standards for Antimicrobial Susceptibility Testing; Fourteenth Informational Supplement. NCCLS document M100-S14. NCCLS, Wayne, PA
42. C. Marodi et al. P594 intracellular killing of drug-resistant Staphylococcus aureus by different antibiotics Clin. Microbiol. Infect. 10 2004 593